3 ‘Perfect 10’ Stocks That Have Legs For Future Gains

 | Nov 19, 2020 05:44AM ET

A combination of factors – including the recent election, a growing ‘new wave’ of coronavirus cases, and the prospect of COVID vaccines on the market before year’s end – are buffeting the markets in recent weeks. The major impact, for now, appears to be the vaccine news. Pharma giants Pfizer and Moderna have both announced successful trials, with Pfizer’s vaccine showing 90% effectiveness and Moderna’s 94%.

The vaccine announcements are important, for public health but also for the economy. Numerous states are preparing new lockdown regimes which are certain to stifle economic activity – but a vaccine release will give state governors and legislators support in reopening. Even the announcement that such vaccines are showing success in late-stage trials was enough to boost stocks; the actual release for public distribution is sure to have a greater effect.

Wall Street’s analysts have been busy in recent weeks and days, scanning the market for stocks that are likely gainers in the weeks ahead. They are tagging plenty of choices, but some stocks stand out. These are the ones with ‘Perfect 10’ from the Smart Score .

The Smart Score is a unique tool that uses an array of 6 separate factors, each of which is known to correlate with future overperformance. The Smart Score gives investments a single-digit rating, letting investors know at a glance where the stock is likely going – according to quantifiable data.

Here, we look at three stocks that score a Perfect 10. Let’s find out what lies behind this rating.

Hanesbrands ( )

Hanesbrands Inc (NYSE:HBI) is undoubtedly one you are familiar with. Hanes is a clothing manufacturer, specializing in undergarments, whose brands includes Hanes, Playtex, L’eggs, Champion, and plenty more. The company’s garments are somewhat ubiquitous, reflecting their necessity, and these modest products brought in over $7 billion in revenue last year.

This year, Hanes, like much of the retail world, took a hit in the first quarter when the corona pandemic forced a general economic shutdown. But the company quickly rebounded, and the Q3 revenues, at $1.81 billion, were the highest of the last four quarters. Earnings show a more mixed picture; Q2 EPS came in at an excellent 60 cents, while Q3 showed a 30% drop to 42 cents. That drop, however, still left the Q3 earnings in line with previous years’ results.

The earnings report, with its combination of beating the estimate while falling year-over-year, pushed the stock down in recent sessions. Even so, HBI has clearly recovered its value since hitting bottom in the ‘corona recession.’ The stock is up ~90% from its low point this year. Adding to the attraction, Hanes has kept up its regular stock dividend, maintaining the payout at 15 cents per common share, for all of 2020. That dividend is now yielding an above-average 4.6%.

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

On the insider front, two transactions, both by Ronal Nelson of the Board of Directors, have swung the sentiment needle on Hanes well into positive territory. In the last five days, Nelson has purchased over $1 million worth of shares, in two tranches, one of 50,000 shares and the other of 30,000.

Covering Hanesbrands for Raymond James, analyst Matthew McClintock notes the company’s strong current position.

“We believe that HBI’s 3Q20 results signal a continuation of market share gains in its core categories driven by the company’s inherent competitive advantages of scale, strong brands, and in-house supply chain,” the 5-star analyst noted.

In addition, McClintock believes the company demonstrates its ability to adapt to the coronavirus scene: “HBI’s protective garment businesses is expected to slow meaningfully going forward. This recently developed business line to help fight the pandemic generated $179 million in revenues during 3Q20 (reflecting 10% of revenues) — surpassing HBI’s previous 2H20 outlook of $150 million.”

McClintock rates HBI a Strong Buy, and his $16 price target suggests it has a 22% upside from current levels.

Other analysts are on the same page. With 4 Buys and 1 Hold received in the last three months, the word on the Street is that HBI is a Strong Buy. (See HBI stock analysis )